Brain Metastases Treatment
Brain Metastases Treatment
Treatment is decided by four findings together: how many deposits there are and where they sit, what the cancer outside the brain is doing, what molecular markers it carries, and how the patient is currently functioning. The methods are surgery, precisely aimed radiotherapy, whole-brain radiotherapy and drug treatment selected by marker, and they are frequently combined rather than chosen one at a time. Steroids relieve the swelling around deposits within days, and anti-epileptic drugs are used for patients who have had a seizure.
How the decision is made
There is no single sequence that applies to everyone, and the reason is that this is a disease of the whole body with a local problem in the brain. The four questions below, taken together, produce the recommendation:
- How many deposits, and where? A limited number can each be treated precisely with focused radiotherapy; a large number or widespread involvement usually calls for a different approach. A deposit that is large, causing pressure, or sitting in an area that can be operated on safely is considered for surgery.
- What is the disease outside the brain doing? If the cancer elsewhere is controlled, treating the brain deposit aggressively makes sense. If it is progressing widely, treatment is aimed at the cancer as a whole, with the brain deposits treated in a way that relieves symptoms and does not cost time.
- What markers does the cancer carry? In several cancers, a drug chosen by marker reaches the brain effectively, and starting it can treat the deposits and the rest of the disease together. In that situation, drug treatment may come first, with imaging repeated after a short interval to confirm that it is working.
- How is the patient functioning, and what do they want? A plan that cannot be tolerated is not a plan, and the intensity of treatment is matched to what the patient can undergo and to what matters to them.
Two principles follow from this. The first is that the brain problem and the body problem are treated as one, since a sequence that ignores either leaves a gap. The second is that the order of treatment can change as the disease changes, which is why the plan is reviewed rather than fixed at the outset, and why imaging at defined intervals is part of the treatment rather than a follow-up formality.
Surgery: removing a deposit
An operation to remove a deposit is used less often than radiotherapy, but it is the fastest way to relieve pressure and it produces tissue for testing. It is considered in these situations:
- A single deposit that is large or causing significant pressure, where the mass effect rather than the tumour biology is the immediate problem.
- A deposit in an accessible site, where removal can be achieved without damaging tissue that controls movement, speech or vision.
- When the diagnosis is uncertain, or when no primary cancer has been identified, since the tissue removed answers the question.
- A deposit that has bled, seen particularly with melanoma and with kidney cancer, where removal both relieves the pressure and deals with the blood.
- Followed by treatment to the cavity — after a deposit is removed, radiation to the site is usually considered, because treating the cavity reduces the chance of the tumour returning there.
What an operation does not do is deal with deposits that cannot be seen or that lie in tissue that cannot be removed. That is why the imaging before surgery has to find every deposit rather than the largest one, and why surgery is often combined with radiotherapy to the cavity or to other deposits. Where a deposit lies close to areas that control speech or movement, the operation is planned with mapping and monitoring so that function guides how far removal can go.
Focused radiotherapy for a limited number of deposits
Stereotactic radiosurgery delivers a single, high-precision, high-dose treatment to a deposit without opening the skull, and is the standard approach when the number of deposits is limited:
- How it works — many beams are aimed so that they converge on the deposit, delivering a high dose where they meet while each individual beam contributes little to the tissue it passes through.
- What it is used for — deposits that are relatively small and well defined, in a limited number, including deposits that are not in a site where surgery is safe.
- Given to a surgical cavity — after a deposit has been removed, the same technique is used to treat the cavity, which lowers the chance of recurrence at that site.
- Why the number matters — each deposit needs its own plan, and treating very many individually becomes impractical, which is where whole-brain treatment or a drug-based approach is considered instead.
Focused radiotherapy is preferred where it can be used because it delivers a very high dose to the deposit and a much lower dose to the rest of the brain. That difference is what protects memory and thinking, and it is the reason the number of deposits is counted so carefully before the decision is made.
Drug treatment chosen by the markers
For a growing number of patients, the first treatment for deposits in the brain is a drug rather than radiotherapy or surgery, because certain agents reach the brain in effective concentrations:
- Lung cancer with a driver mutation — EGFR, ALK, ROS1 and related targets: several agents in these classes produce responses in the brain, and may be started first in a patient without severe symptoms, with imaging repeated after a short interval.
- HER2-positive breast cancer — HER2-directed treatment, which has changed what is achievable for deposits from this subtype, used alongside local treatment where that is needed.
- Melanoma with a BRAF mutation — BRAF and MEK inhibitors, and immune checkpoint inhibitors, both of which have activity in the brain in this cancer.
- Immune checkpoint inhibitors — relevant mainly in melanoma and lung cancer, and occasionally in others depending on PD-L1 and mismatch-repair status.
- Chemotherapy — used according to the type of cancer, though many conventional drugs penetrate the brain less effectively than the targeted agents and immunotherapies above.
- What testing is required — the markers must be established on tissue, and where the original tissue is no longer available, or where the result differs, the deposit itself can be tested.
Two cautions belong with this. The first is that drug treatment takes weeks to show its effect, so it is not the right choice when a deposit is causing pressure that needs relieving within days — in that situation local treatment comes first, with drug treatment alongside. The second is that a response is assessed by imaging at a defined interval, with local treatment held in reserve, so the plan is a sequence rather than a single decision.
Whole-brain radiotherapy, and when it is used
Treating the whole brain with radiotherapy remains the appropriate option in specific situations, and is used more selectively than it once was:
- Many or widespread deposits, where treating each one individually is not practical, particularly when the deposits are small and numerous.
- Involvement of the fluid spaces, where cancer cells have reached the cerebrospinal fluid, since the whole of the brain and the fluid around it need treating.
- Where the situation is urgent and extensive, and the aim is to control symptoms and the disease within the brain as quickly as is reasonable.
- Delivered with attention to memory — where the anatomy allows, techniques that reduce the dose to the structures involved in memory are used, together with medication that has been studied for this purpose.
- What it involves — a short course of daily outpatient treatment, usually over one to two weeks, with fatigue and hair loss the commonest effects and improvement or stabilisation of symptoms the goal.
- Why its use has narrowed — because focused radiotherapy and drug treatment have improved, and because of the effects of whole-brain treatment on memory and thinking, which is a discussion worth having before treatment rather than after it.
Steroids, seizures and rehabilitation
Part of the treatment is directed at the effects of the deposits rather than at the deposits themselves, and it is the part that determines how the patient feels day to day:
- Steroids reduce the swelling around a deposit and often improve symptoms within a day or two. They are used at the lowest dose that works, and reduced as soon as it is safe, because prolonged use causes weight gain, raised blood sugar, muscle weakness, sleep disturbance and mood change.
- Anti-epileptic drugs are started for patients who have had a seizure, and reviewed at each visit; the aim is control at the lowest effective dose, with attention to how these drugs interact with cancer treatment.
- Preventing clots is considered in patients who are not bleeding in the brain, since cancer increases the tendency for blood clots, and this is weighed against the risk of bleeding into a deposit.
- Rehabilitation — physiotherapy, speech and language therapy, and cognitive support — is treatment rather than an optional extra, and gains continue for months, so it should be planned from the outset and continued after the acute phase.
- Symptom control for fatigue, sleep, appetite and pain, which is addressed directly rather than left as a consequence to be accepted.
- The safety conversation — driving, working at height, swimming and being alone are decided by seizure control and by the deficit present, and should be answered explicitly.
How the plan is made and reviewed
The decisions here sit between two specialties, and they are best made together rather than one after the other:
- Neurosurgery assesses whether a deposit can be removed, and how urgently.
- Radiation oncology plans the focused or whole-brain treatment, including the dose and the volume treated.
- Medical oncology establishes the molecular profile, chooses drug treatment, and manages the cancer outside the brain.
- Neuro-oncology and rehabilitation contribute on symptom control and on what function can be recovered.
- The sequence is reviewed rather than fixed — imaging at defined intervals is used to confirm that the plan is working, and the order of treatments can be changed if it is not.
- One written plan, with dates, listing what is happening when, what each treatment is for, what would change the plan, and who to contact between reviews.
Because the disease behaves differently from one patient to the next, such a plan is more useful than a general statement of what is possible. Where the assessment leads to the conclusion that the most effective option is a drug chosen by marker, the plan should say so explicitly, with the reasoning — and the patient should be able to see which findings led to which recommendation, because those findings are what would change it.